Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amikacin CSF Penetration in Gram-negative Meningitis
NCT00362245Phase 4Withdrawn
- Sponsor
- Rambam Health Care Campus
- Start
- Sep 2006
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of amikacin in Gram-negative meningitis, sponsored by Rambam Health Care Campus. Primary endpoints: Bactericidal effect on the causative bacteria and Blood and CSF AUC/MIC relationship. Planned start Sep 2006; status: withdrawn.
02
Drugs
amikacin
03
Conditions
Gram-negative meningitis
Beyond the preview
Go deeper on NCT00362245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362245.